Insulin lispro biosimilar (Sanofi)

赖脯胰岛素生物类似药（赛诺菲）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin lispro biosimilar (Sanofi)
Drug Alias Name赖脯胰岛素生物仿制药（赛诺菲）AdmelogSAR-342434
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/07/18
Country/TerritoryUnited StatesPolandRomania +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis U.S. LlcSanofi Winthrop Industrie SA
Inactive CompaniesSanofi
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB04A10AC04A10AD04
Related LinksN/A